MICHAEL HOBBS: Open Payments
NPI 1174032213 · MEMPHIS, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,988 in 164 payments from 17 companies in 2025. Trend: 2023 $10,253 · 2024 $3,867 · 2025 $2,988
Food & beverage: $2,988
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 23 | $425 |
| Otsuka America Pharmaceutical, Inc. | 30 | $419 |
| Neurocrine BioSciences, Inc. | 20 | $378 |
| ABBVIE INC. | 17 | $370 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $365 |
| Alkermes, Inc. | 15 | $294 |
| Vanda Pharmaceuticals Inc. | 9 | $155 |
| Janssen Pharmaceuticals, Inc | 9 | $155 |
| Collegium Pharmaceutical, Inc. | 7 | $109 |
| Supernus Pharmaceuticals, Inc. | 5 | $91 |
Products named: Auvelity, REXULTI, INGREZZA, VRAYLAR, CAPLYTA, ARISTADA, HETLIOZ, INVEGA SUSTENNA.
Industry payments across TN — which companies pay providers there.
